Lazić, Jelena (7004184322)Jelena (7004184322)LazićJanić, Dragana (15729368500)Dragana (15729368500)JanićKrstovski, Nada (24724852600)Nada (24724852600)KrstovskiRodić, Predrag (15846736800)Predrag (15846736800)RodićMilošević, Goran (55608514200)Goran (55608514200)MiloševićJanković, Srdja (26023181300)Srdja (26023181300)JankovićBrašanac, Dimitrije (6603393153)Dimitrije (6603393153)BrašanacDokmanović, Lidija (15729287100)Lidija (15729287100)Dokmanović2025-06-122025-06-122016https://doi.org/10.2298/SARH1608413Lhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84988666421&doi=10.2298%2fSARH1608413L&partnerID=40&md5=9e22a24d67d082ac4fd521c6ddc13ebchttps://remedy.med.bg.ac.rs/handle/123456789/7947Introduction Intensive treatment protocols used for non-Hodgkin lymphoma in children lead to eventfree survival rates ranging from 80% to 90%. However, the results are less successful in developing countries. Lymphoblastic lymphoma (LBL) is the second most frequent type of lymphoma in children, contributing with about one third to all non-Hodgkin lymphoma in childhood. Objective The aim of the study was to evaluate the results of LBL treatment in University Children’s Hospital (UCH), Belgrade. Methods A retrospective analysis of patient records at UCH from 1997 to 2015 was carried out in patients aged 0–18 years, in whom the diagnosis of LBL had been established. Twenty-two children were included in the analysis. Results Mean age at diagnosis was 10 years, with preponderance of male patients. All patients were treated according to Berlin-Frankfurt-Munster-based chemotherapy protocols. With median follow-up of 91.5 months, five-year probability of event-free survival was 79.5% for all patients, while overall survival was 81.8%. Conclusion Our results, although slightly inferior to those of leading international groups, reflect a good treatment outcome in our patients. © 2016, Serbia Medical Society. All rights reserved.ChildrenLymphoblastic lymphomaPediatricSerbia